Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
A multicenter study of randomized, double-blind, and parallel control of positive drugs was
conducted using a non-inferior design. Eligible neovascular (wet) age-related macular
degeneration (w-AMD) subjects were screened into a trial group and a control group, with the
test group receiving BAT5906 injection and the control group treated with Lucentis®.